Skip to content
Search

Latest Stories

New repeat prescribing toolkit to improve patient care, reduce medicine waste

New repeat prescribing toolkit to improve patient care, reduce medicine waste

By streamlining repeat prescribing systems, the RPS/RCGP toolkit aims to reduce the impact of overprescribing and problematic polypharmacy

The Royal Pharmaceutical Society (RPS) and the Royal College of GPs (RCGP) have launched a new toolkit to enhance the consistency, safety, and efficiency of repeat prescribing systems in general practices across England.

Commissioned by NHS England, this toolkit is the first national good practice guidance for repeat prescribing in two decades and aims to address issues highlighted by the 2021 National Overprescribing Review.


The review recognised the impact that poorly operated repeat prescribing can have on overprescribing and problematic polypharmacy.

Over 1 billion prescriptions are dispensed annually in England, 77% of which are repeat prescriptions, which account for nearly 80% of NHS primary care medicine costs.

The sheer volume and workload of repeat prescriptions underscore the need for streamlined and improved processes.

The RPS/RCGP Repeat Prescribing Toolkit allows GP practice teams and primary care networks, working in collaboration with community pharmacies and patients, to create a “collaborative, safe and efficient” repeat prescribing process.

This approach aims to enhance patient care by addressing inconsistencies and potential oversupply, whilst reducing unnecessary medicines waste and saving NHS resources.

Clare Howard, RPS Fellow and Clinical Lead author, noted that this toolkit marks a significant step forward in ensuring the safety and efficiency of repeat prescribing systems, ultimately benefiting patients and the NHS as a whole.

“By working together, the RPS and RCGP have developed practical guidance and useful resources which will enable GP practices and Primary Care Networks to self-assess their current arrangements and make meaningful improvements in their repeat prescribing processes,” she explained.

The toolkit also includes practical guidance on improving communication with patients about repeat prescribing, supported by good practice case studies, flow charts, action plan templates, and useful resources.

Dr Michael Mulholland, Honorary Secretary of the RCGP, emphasised that safe and appropriate prescribing is a key skill for GPs, and they take it “very seriously”

“Repeat prescribing makes up a large part of the general practice workload and we need to make sure we are always streamlining and improving the process,” he said.

To complement the toolkit, a new NHS dashboard has been developed to highlight potential oversupply of medicines in various prescribing areas. The dashboard will support improvement initiatives, particularly by identifying inconsistencies in repeat prescribing processes, to help minimise avoidable waste and the risk of patient harm.

Graham Prestwich, patient representative and Board Member at Healthwatch Leeds, stated that the toolkit and associated resources will help make communicating with patients about their repeat medicines “simpler and more effective."

Professor Tony Avery, National Clinical Director for Prescribing at NHS England, emphasised the importance of the tool, stating: “With over one billion prescriptions dispensed annually in England, over three quarters of which are repeat prescriptions, it is essential that repeat prescribing systems in general practices are safe for patients and efficient for all involved.”

The toolkit is now available for use by general practices, Primary Care Networks, Integrated Care Boards, and community pharmacies across England.

More For You

Community pharmacy needs investment and support to deliver neighbourhood health, says CCA chief

Community pharmacies see patients more than anyone else in the primary care system.

Getty Images

Community pharmacy key to neighbourhood health, but investment needed, says CCA chief

Community pharmacies can play a vital role in delivering a ‘neighbourhood health service’, provided they receive the necessary investment and support, according to Malcolm Harrison, chief executive of the Company Chemists’ Association (CCA).

Harrison's comments come in response to a new report from think tank Reform, titled Designing a Neighbourhood Health Service, which outlines key principles for achieving the government's vision of a more community-focused healthcare system.

Keep ReadingShow less
Mike Hewitson, superintendent pharmacist & managing director of Beaminster Pharmacy

Mike Hewitson elected as NPA board member for England

Mike Hewitson elected as NPA board member for England: New term begins April

Mike Hewitson, superintendent pharmacist & managing director ofBeaminster Pharmacy, has been elected as the next National Pharmacy Association (NPA) board member for England.

Since 2023, Hewitson has served as chair of Community Pharmacy Dorset. He is also a member of Somerset Council and a Non-Executive Director at HubRx.

Keep ReadingShow less
Store closures 2024: Chemists among hardest hit

Over 600 chemist shops belonging to multiples and chains were closed last year

Getty Images

35 shops closed per day last year, chemists worst affected

More shops are expected to exit the UK high streets driven by driven by rising operational costs and a continued shift towards online shopping and transactions.

According to figures from PwC, a total of 12,804 outlets operated by chains (those with five or more locations) exited high streets, shopping centres and retail parks in 2024 – equivalent to 35 closures per day.

Keep ReadingShow less
Empty pharmacy shelves due to UK medicine shortages.

The government has said it's investing up to £520m to manufacture more medicines

Pic credit: iStock

Brexit blamed for UK medicine shortages with "little sign of recovery"

The UK is facing “a worsening situation” with drugs shortages compared to the rest of Europe as a result of Brexit, according to the Nuffield Trust health thinktank.

It comes of the back of data that revealed that the department of health and social care (DHSC) received 1,938 notifications of disruptions to medicine supply last year – the highest in four years.

Keep ReadingShow less
Alert! Patients on Promixin should be switched to alternatives by 30 April

Promixin is licensed for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in adults and children with cystic fibrosis

Getty Images

Medicine shortage: Promixin to be discontinued from May 2025

The Department of Health and Social Care (DHSC) and NHS England have issued a national patient safety alert regarding the upcoming shortage of Promixin (colistimethate).

The alert, issued on 17 March 2025, states that Promixin (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) will be discontinued from early May 2025, with stocks expected to be exhausted by this time.

Keep ReadingShow less